Galena Biopharma (GALE) Will Present GALE-301/GALE-302 Phase 1/2a Data at AACR 2016
Tweet Send to a Friend
Galena Biopharma, Inc. (NASDAQ: GALE) announced that data from the booster phase of the Company’s GALE-301/GALE-302 Phase 1/2a clinical trial ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
